STOCK TITAN

Optimi Health proposes 200-person OPTI-101 trial redesign

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Optimi Health Corp. outlined plans for OPTI-101 and OPTI-201 clinical programs and a proposed shares-for-debt settlement. OPTI-101’s Phase 2b protocol amendment is under Health Canada review; it would change the originally authorized single-arm, open-label study to a randomized, double-blind, active placebo-controlled trial in 200 adults with severe major depressive disorder. Dosing is expected in Q1 2027, with topline data expected in 2028.

OPTI-201’s Phase 3 study is expected to begin in 2027. Optimi is assuming sponsorship of the open-label study, which has a Health Canada No Objection Letter and would enroll 100 veterans and front-line workers with PTSD. The company plans to file a U.S. IND for OPTI-201 in 2027 and expects to produce its first finished-dose ibogaine capsules in the coming weeks for prospective ARPA-H-funded research.

The proposed settlement would issue 114,285 shares at US$2.10 each to settle US$240,000 of compensation owed to Chief Executive Officer Dane Stevens for October 2024 to October 2026. It is subject to negotiation of a definitive agreement and any required regulatory approval. Optimi says its psychedelic products’ safety and efficacy remain under investigation and none has received market authorization from Health Canada or the FDA.

Filing Explained

The company says it expects to fund the planned OPTI-101 Phase 2b trial from cash on hand, making existing company cash the intended funding source; this is a plan, not a report that trial costs have already been paid.

OPTI-101 Phase 2b trial size 200 adults Adults with severe major depressive disorder in the proposed trial
OPTI-101 dosing Q1 2027 Dosing is expected to begin in this quarter
OPTI-101 topline data 2028 Topline data are expected in this year
OPTI-201 Phase 3 study size 100 participants Veterans and front-line workers with PTSD
OPTI-201 Phase 3 initiation 2027 Study initiation is expected in this year
Compensation debt proposed for settlement US$240,000 Compensation owed to Dane Stevens for October 2024 to October 2026
Proposed share issue price US$2.10 per share Price for the Debt Settlement Shares
Proposed Debt Settlement Shares 114,285 shares Issuance to settle compensation owed to Dane Stevens, subject to stated conditions
active placebo medical
"versus an active placebo"
Montgomery-Åsberg Depression Rating Scale (MADRS) medical
"a MADRS score of 30 or higher"
A 10-question clinician-rated scale that measures the severity of depressive symptoms and tracks changes over time, often used in clinical trials as a standardized “thermometer” for depression. Investors watch MADRS results because improvements or lack of change can drive trial success, regulatory decisions and ultimately a drug’s commercial prospects, much like an exam score signals whether a new product meets expectations.
monotherapy medical
"OPTI-101 is evaluated as monotherapy"
Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.
Investigational New Drug (IND) regulatory
"preparing an Investigational New Drug (IND) application to the FDA"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
No Objection Letter regulatory
"holds a Health Canada No Objection Letter"
A no objection letter is an official note from a regulator or authority saying it has no problem with a proposed action—such as a transaction, filing, or plan—and will not block it. Think of it as a formal green light that lowers the chance of unexpected regulatory roadblocks, shortens timelines, and can make a deal or announcement more likely to proceed as priced by the market, which matters to investors assessing risk and timing.
Notice of Compliance with Conditions (NOC/c) regulatory
"future Health Canada submission for a Notice of Compliance with Conditions (NOC/c)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many people are in OPTH’s proposed OPTI-101 Phase 2b trial?

The proposed study is designed for 200 adults with severe major depressive disorder.

When does OPTH expect OPTI-101 dosing and topline data?

Optimi expects OPTI-101 dosing to begin in Q1 2027, with topline data expected in 2028.

What is the primary endpoint in OPTH’s OPTI-101 Phase 2b trial?

The primary endpoint is change in MADRS at Week 3, assessed by independent central raters blinded to treatment; Week 6 is the pre-specified alternative.

How many shares does OPTH propose to issue in its debt settlement?

The proposed settlement covers 114,285 shares at US$2.10 per share for compensation owed to Chief Executive Officer Dane Stevens.

What conditions apply to OPTH’s proposed shares-for-debt settlement?

The issuance is subject to negotiation of a definitive agreement and obtaining any required regulatory approval. The shares would have a statutory hold period expiring four months and one day after issuance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-43304

Optimi Health Corp.
(Translation of registrant's name into English)

269 David Brown Way
Princeton, B.C. V0X 1W0
Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 


EXHIBIT INDEX  

Exhibit Description of Exhibit
   
99.1 Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Optimi Health Corp.    
  (Registrant)
   
  
Date: November 18, 2026     /s/ Dane Stevens    
  Dane Stevens
  Chief Executive Officer, Chief Marketing Officer and Director
  

EXHIBIT 99.1

logo 

Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement

Proposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power; dosing expected Q1 2027 with topline data expected in 2028

Health Canada-cleared Phase 3 trial of OPTI-201 MDMA-assisted therapy in 100 veterans and front-line workers with PTSD expected to begin in 2027; Company plans to file a U.S. IND for OPTI-201 in addition to the proposed Canadian trial.

VANCOUVER, British Columbia, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical drug developer and manufacturer of regulated psychedelic drug products, provides an update on its clinical programs, commercial supply, Ibogaine Initiative and a shares-for-debt settlement.

Highlights

OPTI-101: naturally derived psilocybin for major depressive disorder (MDD)

Phase 2b Trial: randomized, double-blind, active placebo-controlled trial in 200 adults with severe MDD; dosing expected to begin in Q1 2027; topline data expected in 2028.
U.S. FDA Pathway: preparing an IND for the FDA ahead of a planned U.S. Phase 3 trial for the same indication.
Natural Psilocybin Alternative: positioned as a naturally derived alternative to the synthetic psilocybin products advancing toward FDA approval.

OPTI-201: MDMA for post-traumatic stress disorder (PTSD)

Phase 3 Trial: Health Canada-cleared study in 100 veterans and front-line workers; initiation expected in 2027.
MDMA Market Opportunity: prescribed in Australia since October 2024; positioned to enter the U.S. if MDMA-assisted therapy is approved.
Potential U.S. FDA Pathway: IND filing with the FDA planned for 2027, alongside initiation of the Canadian Phase 3.

Ibogaine Initiative

Finished-dose capsules: first in-house production expected in the coming weeks, in various dosage strengths, for prospective ARPA-H-funded research.

“2027 is a pivotal year for Optimi as we advance several product candidates. Our lead product candidate, OPTI-101, is naturally derived psilocybin already prescribed in Australia, with no serious adverse events reported. Subject to Health Canada approval, we expect to begin dosing in a randomized, blinded Phase 2b study, with topline data expected in 2028. OPTI-201 is expected to start Phase 3 for veterans and front-line workers, and production of our first ibogaine capsules is weeks away. We are preparing to take these programs to the U.S. Food and Drug Administration (“FDA”),” said JJ Wilson, Chairman of the Board.

The safety and efficacy of Optimi’s regulated psychedelic drug products are still under investigation, and none of those products has received market authorization by Health Canada.

OPTI-101: Natural Psilocybin for MDD

OPTI-101, the Company’s lead product candidate, is a capsule of naturally derived psilocybin, manufactured entirely in-house under GMP at Optimi’s Health Canada-licensed facility in Princeton, British Columbia, from biomass cultivation through extraction, encapsulation, testing and packaging. The same capsule is prescribed commercially in Australia, with clinical and commercial supply sharing one formulation and one Chemistry, Manufacturing and Controls (CMC) file.

The most advanced psilocybin programs in the United States use synthetic psilocybin and are moving toward potential FDA approval. Optimi is developing OPTI-101 as a naturally derived alternative to synthetic psilocybin. OPTI-101 is expected to be supported by controlled clinical trial data and real-world evidence from Australia, where it is currently prescribed outside clinical trials for Treatment-Resistant Depression.

Phase 2b Trial Design: A multi-site, randomized (1:1), double-blind, parallel-group trial of a single dose of OPTI-101 psilocybin versus an active placebo in 200 adults with severe MDD, with identical psychological support in both arms. The amended protocol, which converts the originally authorized single-arm, open-label study, is under review by Health Canada.

Population: adults aged 18 to 65 with severe MDD and a Montgomery-Åsberg Depression Rating Scale (MADRS) score of 30 or higher, confirmed by a blinded central rater. Serotonergic antidepressants are discontinued before dosing, so OPTI-101 is evaluated as monotherapy.
Primary endpoint: change in MADRS at Week 3, assessed by independent central raters blinded to treatment; Week 6 is the pre-specified alternative.
Key secondary endpoints: change in MADRS at Weeks 6 and 12, and in the Sheehan Disability Scale at Week 12.
Durability and safety: response, remission and time to relapse reported through 12 months, with measurements at 3, 6 and 12 months; Columbia-Suicide Severity Rating Scale (C-SSRS) at every visit and review by an independent Data Safety Monitoring Committee.

Enrollment and dosing are expected to begin in Q1 2027, with topline data expected in 2028. Topline data will include the primary and key secondary endpoints and durability through six months, following database lock after the last participant’s Week 26 visit. Twelve-month durability data are expected to follow. No interim efficacy analysis is planned. Optimi owns the full dataset and expects to fund this trial from cash on hand.

U.S. IND and Planned Phase 3: Optimi is preparing an Investigational New Drug (“IND”) application to the FDAfor OPTI-101. Subject to Phase 2b results and FDA clearance, Optimi plans a U.S. Phase 3 trial of OPTI-101 in MDD.

Current Use (Australia): Optimi has supplied OPTI-101 capsules to Australian prescribers since September 2025 under the TGA Authorised Prescriber scheme for Treatment-Resistant Depression. No serious adverse events have been reported, according to adverse event data made public through a freedom of information request. Patient outcomes are captured through Australia’s national patient registry with the Australian National University. Optimi expects to report an update in 2027 and intends to include these data in a future Health Canada submission for a Notice of Compliance with Conditions (NOC/c).

OPTI-201: MDMA for PTSD

OPTI-201, the Company’s late-stage product candidate, consists of GMP MDMA capsules manufactured in Canada and prescribed for PTSD in Australia since October 2024, where treatment for veterans can be funded by the Department of Veterans’ Affairs.

Phase 3 Trial Design: Optimi is assuming sponsorship of a multi-site, open-label Phase 3 study of MDMA-assisted psychotherapy in 100 veterans and front-line workers with PTSD, which holds a Health Canada No Objection Letter. Participants receive two supervised dosing sessions two to three weeks apart. Initiation is expected in 2027.

Population: veterans and current or former front-line workers with PTSD, including military, police, paramedics, firefighters and healthcare workers.
Primary endpoint: change in Clinician-Administered PTSD Scale (CAPS-5) total severity score from baseline to Week 8.
Key secondary endpoint: change in functional impairment.

U.S. IND: With MDMA-assisted therapy for PTSD before the FDA, Optimi intends to position OPTI-201 as a potential MDMA alternative in the United States if it is approved, supported by its own Phase 3 data and more than two years of commercial supply and related data from Australia. The Company plans to file an IND with the FDA for OPTI-201 in 2027.

Ongoing Commercial and Clinical Supply

Optimi has exported GMP MDMA and psilocybin from Princeton since 2024 to Australian prescribers, for a planned Phase 2 trial in the United Kingdom and for MAPS-sponsored MDMA trials in Israel. In Canada, its psilocybin is available through Health Canada’s Special Access Program.

Ibogaine Initiative Update

Optimi expects to produce its first finished-dose ibogaine capsules in-house in the coming weeks. The Company is working to make these products available to U.S. ibogaine research funded by the Advanced Research Projects Agency for Health (ARPA-H).

Shares-for-Debt Settlement

The Board approved the issuance of common shares to settle US$240,000 of unpaid compensation owed to Chief Executive Officer Dane Stevens for October 2024 to October 2026, accrued at US$120,000 per year (the “Debt Settlement”). The shares will be issued at US$2.10per share, for 114,285shares in total (the “Debt Settlement Shares”). The Debt Settlement is subject to the negotiation of a definitive agreement and obtaining any required regulatory approval.

The Debt Settlement Shares will be subject to a statutory hold period expiring four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.

Related Party Transaction and Insider Participation

The issuance of the Debt Settlement Shares to Mr. Stevens is considered a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions (“MI 61-101”) because Mr. Stevens is a director and senior officer of the Company. The issuance of the Debt Settlement Shares, as it relates to Mr. Stevens, is exempt from the formal valuation and minority approval requirements of MI 61-101 pursuant to subsections 5.5(a) and 5.7(1)(a) of MI 61-101 respectively, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction exceeds 25% of the market capitalization of Optimi. The directors of the Company unanimously approved the Debt Settlement, with Mr. Stevens declaring his interest and abstaining from voting. No materially contrary view or abstention was expressed or made by any other director of the Company in relation thereto. The Company did not file a material change report more than 21 days before closing because the terms of the Debt Settlement were finalized shortly before the announcement and the Company wished to reduce its liabilities without delay. The Company expects to file a material change report in the coming days.

Company Contact:
JJ Wilson, Chairman of the Board
Telephone: (778) 761-4551
Email: investors@optimi.net

About Optimi Health Corp.

Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) is a commercial-stage pharmaceutical company manufacturing and distributing GMP-grade psychedelic drug products for mental health. As a Health Canada-licensed manufacturer, Optimi produces validated MDMA and naturally derived psilocybin drug products at its GMP facilities in British Columbia, Canada, and supplies active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally. Its products are prescribed to patients in Australia under the Authorised Prescriber scheme and are accessible in Canada through the Special Access Program. Optimi is developing OPTI-101, its lead product candidate, a naturally derived psilocybin capsule, for major depressive disorder, and OPTI-201, its late-stage MDMA product candidate, for post-traumatic stress disorder. The safety and efficacy of psilocybin and MDMA-assisted therapy remain under investigation, and none of Optimi’s drug products has received market authorization from Health Canada or the FDA.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable Canadian and United States securities legislation (collectively, “forward-looking statements”), including statements regarding the Company’s plans for 2027, the design, conduct, funding and timing of the OPTI-101 Phase 2b and OPTI-201 Phase 3 trials, Health Canada review of the amended Phase 2b protocol, the expected timing of topline data and twelve-month durability data, the preparation and filing of INDs for OPTI-101 and OPTI-201, a planned U.S. Phase 3 trial, the Company’s competitive positioning in the United States, the expectation that OPTI-101 will be supported by controlled clinical trial data, the use of real-world evidence and a future NOC/c submission, future exports, ibogaine development and availability, ARPA-H-funded research and the Debt Settlement, including its terms and the associated conditions to closing. These statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including delays in clinical trial initiation, enrollment or completion, clinical results, decisions by Health Canada, the TGA, FDA or other regulators, U.S. controlled substance requirements, import and export permits, the availability of financing, market conditions, and risks described in the Company’s continuous disclosure filings available on SEDAR+ and EDGAR. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Except as required by law, the Company undertakes no obligation to update them.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Filing Exhibits & Attachments

1 document

Keep reading